Intestinal Flora Research Plan for Critically Ill Patients
NCT ID: NCT04455061
Last Updated: 2020-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2020-01-01
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The gut provides the microbiome with habitat and the nutrients it needs, down-regulates the immune response to form immune tolerance, and promotes its colonization in the intestine.Under physiological conditions, the mutually beneficial symbiosis of the intestine and microorganisms promotes the body's homeostasis. The composition and biodiversity of the microbial community are highly susceptible to various factors, including diet, environment, drugs, infections, inflammation, etc. Especially for acute stress, severe stress, the use of broad-spectrum antibiotics, vasoconstrictors and opioids, intestinal ischemia/reperfusion injury, epithelial cell apoptosis, barrier integrity destruction, gastrointestinal Changes in the motility of the tract, lack of nutrients in the intestinal cavity, etc. All those can lead to rapid changes in the intestinal flora, and this change can last for a long time; manifested by the loss of the richness and diversity of the intestinal microflora (especially the symbiotic flora), The ratio of Bacteroidetes/thickwalled bacteria is severely unbalanced, and a single flora (often a potential pathogen) overgrows, that is, bacterial flora imbalance or microecological disturbance.
At present, for critically ill patients, there are few relevant studies, and currently limited to small-scale, single cross-sectional studies. These studies have uncovered the changes and impacts of intestinal microbiota in critically ill patients in ICU, but they are still in the stage of touching the image of blind people. The relevant mechanisms and dynamic changes and their significance are unclear, requiring large-scale, dynamic, continuous and comprehensive In order to accurately grasp the role of intestinal flora in the development and prognosis of the disease, we hope to accurately control the intestinal flora and achieve effective treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS) on the Respiratory Physiology in Patients With Prolonged Mechanical Ventilation
NCT07002710
Gut Microbiota Analysis in IAI Patients With Sepsis-associated Liver Dysfunction
NCT05628493
Microbiome Dysfunction in Surgical Intensive Care Unit Survivors
NCT05357170
Long-term Follow up in Survivors of Critical Illness
NCT04608994
Gut-Brain-Axis/Lung-Brain-Axis and Mental Ill Health in Critical Illness
NCT05580367
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Due to the decline in organ function reserve of elderly patients, chronic diseases of basic heart, lung, kidney and other systems are often combined. After suffering trauma and severe infection, organ function disorders or failures are prone to occur and stay in the ICU ward. With the advent of an aging population, such patients are increasing year by year. It is a heavy burden on society and a huge challenge for the future development and progress of ICU.
The gut flora is involved in a wide range of functions, food digestion, hormone production, and the development and maturation of the immune system. After more than a billion years of co-evolution, a stable symbiotic relationship has been formed between mammals including humans and the gut microbiota. The gut provides the microbiome with habitat and the nutrients it needs, down-regulates the immune response to form immune tolerance, and promotes its colonization in the intestine; accordingly, the gut symbiotic microbiota promotes the health of the body in various ways to form symbiosis Mode: (1) Inhibiting the colonization of pathogenic bacteria by competing for niche and nutrients, producing virulence factors, and secreting bacteriocins, preventing their overgrowth, and protecting the body from pathogen infection, called colonization resistance; (2 ) Promote the proliferation of epithelial cells, secrete antimicrobial peptides and mucus to maintain the integrity of the intestinal barrier; (3) Indirectly regulate the differentiation of innate and adaptive immune cells located in the intestinal epithelial barrier and the whole body, promote the development and maturation of the immune system, and strengthen immune cells Function; (4) Induce extravascular tissue factor-protease activated receptor 1 (TF-PAR1) signal transduction, promote small intestine angiogenesis; (5) participate in hormone signal transduction, regulate intestinal endocrine function; (6) participate in intestinal origin Serotonin (5-HT) metabolism and intestinal neuro-immune cooperation, regulate gastrointestinal motility; (7) produce short-chain fatty acids (SCFAs) by fermenting dietary fiber, improve glucose homeostasis and insulin sensitivity, participate in anti-inflammatory, Promote intestinal motility; (8) Synthesize essential vitamins and neurotransmitters and metabolize bile salts; (9) Participate in body drug metabolism and poison removal. This shows that under physiological conditions, the mutually beneficial symbiosis of the intestine and microorganisms promotes the body's homeostasis. The composition and biodiversity of the microbial community are highly susceptible to various factors, including diet, environment, drugs, infections, inflammation, etc. Especially for acute stress, severe stress, the use of broad-spectrum antibiotics, vasoconstrictors and opioids, intestinal ischemia/reperfusion injury, epithelial cell apoptosis, barrier integrity destruction, gastrointestinal Changes in the motility of the tract, lack of nutrients in the intestinal cavity, etc. lead to rapid changes in the intestinal flora, and this change can last for a long time; manifested by the loss of the richness and diversity of the intestinal microflora (especially the symbiotic flora), The ratio of Bacteroidetes/thickwalled bacteria is severely unbalanced, and a single flora (often a potential pathogen) overgrows, that is, bacterial flora imbalance or microecological disturbance.
The local immune inflammatory storm in the intestine is an important cause of the imbalance of the systemic immune inflammatory response, and the hypothalamic metabolism center is an important target for regulating the body's continuous catabolism. In PICS, immunosuppression, inflammation, and catabolism are mutually causal, forming a vicious circle. So what is the reason for severe patients with different primary diseases to have the same PICS after the acute phase? Are there common pathological changes induced by PICS in severe patients? If further studies can be made to clarify the initiating factors of PICS and the path of occurrence and development of PICS, it is undoubtedly a new breakthrough in the treatment of PICS and the "fundamental" way to reduce the mortality of PICS patients. Combining our previous research results, applicants speculate as follows:
1\. The intestinal tract is the "promoting point" for the occurrence of PICS in severely ill patients, and it is also the "central organ" that promotes the development of the disease; 2. The disturbance of the micro-ecology of the intestinal tract is an important reason for causing PICS in the body (and may even be the decisive factor) ; 3. Correction of intestinal microecological disturbances can effectively block the path of PICS development.
For the above ideas, specific explanations are as follows:
1. The intestine may be the "promoting point" for PICS in critically ill patients, and it is also the "central organ" that promotes the development of the disease. The reasons are as follows:
* Our previous studies showed that acute gastrointestinal dysfunction is common in severe patients. Whether it is local simple abdominal exposure injury or systemic ischemia-reperfusion injury, it can cause acute gastrointestinal dysfunction; â‘¡The intestine is not only the main organ of digestion and absorption, but also the body's largest immune organ (adult). When the intestine is acutely damaged, the intestine can affect the nutritional metabolism center of the hypothalamus through Grelin and other hormones, leading to refractory catabolism and exogenous nutrition. At the same time, the local inflammatory reaction of the intestinal tract can also cause an imbalance of the body's immune inflammatory response. In addition, changes in central metabolism in critically ill patients are related to hypothalamic inflammation (indicating that the intestine is "capable" to become the central organ that promotes the occurrence and development of PICS).
Intestinal microecological disturbance is an important cause of PICS Under normal physiological conditions, the intestine has powerful barrier functions, such as physical barrier, chemical barrier, immune barrier, and biological barrier. Especially its biological barrier function plays an important role in the body's metabolism and immunity. There is a stable symbiotic relationship between the human body and the intestinal microbiota. The intestine provides the microbiome with habitat and the nutrients it needs to downregulate the immune response to form immune tolerance and promote its colonization in the intestine; accordingly, the physiological state Next, the gut symbiotic microbiota also maintains the body's health in various ways \[2\]. The intestine and microorganisms are symbiotic and promote the body's homeostasis. However, the composition and biodiversity of the microbial community are highly susceptible to various factors, including diet, environment, drugs, infections, inflammation, etc.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Expect to stay in the ICU for more than 7 days after enrollment;
3. Initial disease, not receiving ICU special treatment;
2. Complicated with perianal infection, intestinal fistula, short bowel syndrome, chronic severe gastrointestinal disease;
3. Patients with malignant tumors undergoing chemotherapy and radiotherapy;
4. Taking probiotic preparations within the past 3 months, etc. Intestinal flora regulator.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Medical Association
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Affliated Drum Tower Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chen X, Li H, Huang S, Chen M, Huang S, Zhu Z, You Y, Xu G, Wang Y, Wang R, Yu W. ROLE OF CHANGES IN LIPOPROTEINS, LIPIDOMES, AND GUT MICROBIOTA IN THE PATHOGENESIS OF PERSISTENT INFLAMMATION, IMMUNOSUPPRESSION, AND CATABOLISM SYNDROME: A PROSPECTIVE COHORT STUDY. Shock. 2025 Sep 1;64(3):322-331. doi: 10.1097/SHK.0000000000002634.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-01-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.